Evidence for long-term use of intramuscular interferon beta-1a: an overview of relapse, disability, and MRI data from selected clinical trials.

The treatment options for multiple sclerosis are rapidly changing. With the increasing number of products available to treat this disease, treatment decisions are becoming more complex. Over the years, diagnosis and assessment of treatment efficacy in multiple sclerosis have evolved, but the primary endpoints used to evaluate patients have remained relatively consistent. Relapse rates, magnetic resonance imaging parameters, and disability progression are all key considerations when assessing efficacy for multiple sclerosis treatments. As selection of therapy becomes increasingly complex for both patients and physicians, risk-benefit considerations that incorporate long-term efficacy and safety on an individualized basis will be of greater importance. The information provided in this article will help to elucidate these considerations.